| Caffeine and Methylliberine: A Human Pharmacokinetic Interaction Study | | 2022 |
| Effect of cenobamate on the single-dose pharmacokinetics of multiple cytochrome P450 probes using a cocktail approach in healthy subjects | Clinical and Translational Science | 2021 |
| Application of Physiologically Based Pharmacokinetic Modeling to Evaluate the Drug-Drug and Drug-Disease Interactions of Apatinib | Frontiers in Pharmacology | 2021 |
| In Vitro/In Vivo Correlation for Drug-Drug Interactions | | 2020 |
| Non-vitamin K antagonist oral anticoagulants and sport | Minerva Cardioangiologica | 2020 |
| HPLC methods of fexofenadine quantitative analysis in rabbits’ liver | Farmatsiya I Farmakologiya | 2020 |
| Strategies for Incorporating Pharmacokinetic Studies into Oncology Phase I Trials | | 2020 |
| The possibility of prognosis of progesterone preparations interaction | Russian Journal of Human Reproduction | 2018 |
| 6. Role of Regulatory Science in New Drug Evaluation : Clinical Pharmacology and Pharmacokinetics | Japanese Journal of Clinical Pharmacology and Therapeutics | 2018 |
| Some Methodologic Considerations in the Assessment of Methods for Predicting Pharmacokinetic Drug-Drug Interactions | Clinical Pharmacology in Drug Development | 2017 |
| INFLUENCE OF VILDAGLIPTIN AND GLIQUIDONE COMBINATION ON P-GLYCOPROTEIN FUNCTIONAL ACTIVITY AND EXPRESSION ON THE BACKGROUND OF NORM AND IN EXPERIMENTAL ALLOXAN-INDUCED DIABETES MELLITUS TYPE 2 | I P Pavlov Russian Medical Biological Herald | 2016 |
| IN SILICO MODELING OF METABOLITE KINETICS | | |
| Views on the Therapeutic Needs of Older Adults | AAPS Advances in the Pharmaceutical Sciences Series | 2016 |
| Summary Report of Questionnaire Survey on Current Situation and Issues of Human Mass Balance Study Using Radioisotopes in Japan | Japanese Journal of Clinical Pharmacology and Therapeutics | 2015 |
| Renal Organic Cation and Anion Transport: From Physiology to Genes☆ | | 2014 |
| Evaluation of Time-Dependent CYP3A4 Inhibition Using Human Hepatocytes | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro Characterization of Intestinal Transporter, Breast Cancer Resistance Protein (BCRP) | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro CYP Induction Using Human Hepatocytes | Methods in Pharmacology and Toxicology | 2014 |
| In Vitro Characterization of Renal Transporters OAT1, OAT3, and OCT2 | Methods in Pharmacology and Toxicology | 2014 |
| Membrane Transporters in ADME | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| In Vitro Kinetic Characterization of Transporter-Mediated Permeability | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| Drug-transporter interaction testing in drug discovery and development | World Journal of Pharmacology | 2013 |
| Pharmacokinetic drug interactions in liver disease: An update | World Journal of Gastroenterology | 2016 |
| Drug-Drug Interactions of P-gp Substrates Unrelated to CYP Metabolism | Current Drug Metabolism | 2019 |
| Co-Prescription of QT-Interval Prolonging Drugs: An Analysis in a Large Cohort of Geriatric Patients | PLoS ONE | 2016 |
| Identification and Evaluation of Clinical Substrates of Organic Anion Transporting Polypeptides 1B1 and 1B3 | Clinical and Translational Science | 2019 |
| Irreversible enzyme inhibition kinetics and drug-drug interactions | Methods in Molecular Biology | 2014 |
| Reversible mechanisms of enzyme inhibition and resulting clinical significance | Methods in Molecular Biology | 2014 |
| Case study 4. Predicting the drug interaction potential for inhibition of CYP2C8 by montelukast | Methods in Molecular Biology | 2014 |
| Pharmacokinetics and ADME characterizations of antibody-drug conjugates | Methods in Molecular Biology | 2013 |
| Pharmacogenetics of membrane transporters: a review of current approaches | Methods in Molecular Biology | 2014 |
| Prediction of Hepatic Transporter-Mediated Drug–Drug Interaction from In Vitro Data | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| The Role of Transporters in Drug Development: Regulatory Science Perspectives from the FDA | AAPS Advances in the Pharmaceutical Sciences Series | 2013 |
| INTEGRATED REACTIVE METABOLITE STRATEGIES | | |
| Evaluation of iberdomide and cytochrome p450 drug-drug interaction potential in vitro and in a phase 1 study in healthy subjects | European Journal of Clinical Pharmacology | 2021 |
| The Effect of CYP3A Induction and Inhibition on the Pharmacokinetics of Laquinimod, a Novel Neuroimmunomodulator | Clinical Pharmacology in Drug Development | 2020 |
| Drug Interactions in the Liver | | 2020 |
| Replacing the eleven native tryptophans by directed evolution produces an active P-glycoprotein with site-specific, non-conservative substitutions | Scientific Reports | 2020 |
| Induction of Cytochrome P450 Systems | | 2020 |
| Combinations of common SNPs of the transporter gene ABCB1 influence apparent bioavailability, but not renal elimination of oral digoxin | Scientific Reports | 2020 |
| Drug–Drug Interaction Studies | | 2020 |
| Ibrutinib does not have clinically relevant interactions with oral contraceptives or substrates of CYP3A and CYP2B6 | Pharmacology Research and Perspectives | 2020 |
| Update on Therapeutic Protein-Drug Interaction: Information in Labeling | Clinical Pharmacokinetics | 2020 |
| Assessment of CYP-Mediated Drug Interactions for Evocalcet, a New Calcimimetic Agent, Based on In Vitro Investigations and a Cocktail Study in Humans | Clinical and Translational Science | 2019 |
| Influence of Multidrug Resistance-Associated Proteins on the Excretion of the ABCC1 Imaging Probe 6-Bromo-7-[C]Methylpurine in Mice | Molecular Imaging and Biology | 2019 |
| Lack of Effect of 12-Week Treatment with Risankizumab on the Pharmacokinetics of Cytochrome P450 Probe Substrates in Patients with Moderate to Severe Chronic Plaque Psoriasis | Clinical Pharmacokinetics | 2019 |
| Mass Balance and Drug Interaction Potential of Intravenous Eravacycline Administered to Healthy Subjects | Antimicrobial Agents and Chemotherapy | 2019 |
| Physiologically-Based Pharmacokinetic Models for CYP1A2 Drug-Drug Interaction Prediction: A Modeling Network of Fluvoxamine, Theophylline, Caffeine, Rifampicin, and Midazolam | CPT: Pharmacometrics and Systems Pharmacology | 2019 |
| Effect of CYP3A Inhibition and Induction on the Pharmacokinetics of Suvorexant: Two Phase I, Open-Label, Fixed-Sequence Trials in Healthy Subjects | Clinical Drug Investigation | 2019 |
| EASL Clinical Practice Guidelines: Drug-induced liver injury | Journal of Hepatology | 2019 |
| Non randomized study on the potential of nitisinone to inhibit cytochrome P450 2C9, 2D6, 2E1 and the organic anion transporters OAT1 and OAT3 in healthy volunteers | European Journal of Clinical Pharmacology | 2019 |
| Considerations for Biologic Product Drug-Drug Interactions: A Regulatory Perspective | Clinical Pharmacology and Therapeutics | 2019 |
| Organic Anion Transporter Polypeptide 1B1 Polymorphism Modulates the Extent of Drug-Drug Interaction and Associated Biomarker Levels in Healthy Volunteers | Clinical and Translational Science | 2019 |
| Herb-drug interactions: a novel algorithm-assisted information system for pharmacokinetic drug interactions with herbal supplements in cancer treatment | European Journal of Clinical Pharmacology | 2019 |
| Does In Vitro Cytochrome P450 Downregulation Translate to In Vivo Drug-Drug Interactions? Preclinical and Clinical Studies With 13-cis-Retinoic Acid | Clinical and Translational Science | 2019 |
| A Clinical Drug-Drug Interaction Study Assessing a Novel Drug Transporter Phenotyping Cocktail With Adefovir, Sitagliptin, Metformin, Pitavastatin, and Digoxin | Clinical Pharmacology and Therapeutics | 2019 |
| Physiologically-Based Pharmacokinetic Modeling Approach to Predict Rifampin-Mediated Intestinal P-Glycoprotein Induction | CPT: Pharmacometrics and Systems Pharmacology | 2019 |
| Effect of Fluconazole Coadministration and CYP2C9 Genetic Polymorphism on Siponimod Pharmacokinetics in Healthy Subjects | Clinical Pharmacokinetics | 2019 |
| FDA Public Meeting Report on "Drug Interactions With Hormonal Contraceptives: Public Health and Drug Development Implications" | Journal of Clinical Pharmacology | 2018 |
| In Vitro/In Vivo Correlation for Drug-Drug Interactions | | 2018 |
| Effect of OATP1B1/1B3 Inhibitor GDC-0810 on the Pharmacokinetics of Pravastatin and Coproporphyrin I/III in Healthy Female Subjects | Journal of Clinical Pharmacology | 2018 |
| Interaction between ABCG2 421C>A polymorphism and valproate in their effects on steady-state disposition of lamotrigine in adults with epilepsy | British Journal of Clinical Pharmacology | 2018 |
| CYP3A4-mediated effects of rifampicin on the pharmacokinetics of vilaprisan and its UGT1A1-mediated effects on bilirubin glucuronidation in humans | British Journal of Clinical Pharmacology | 2018 |
| Inhibitory Effects of Commonly Used Excipients on P-Glycoprotein in Vitro | Molecular Pharmaceutics | 2018 |
| A Novel PBPK Modeling Approach to Assess Cytochrome P450 Mediated Drug-Drug Interaction Potential of the Cytotoxic Prodrug Evofosfamide | CPT: Pharmacometrics and Systems Pharmacology | 2018 |
| Drug Interactions With New Synthetic Opioids | Frontiers in Pharmacology | 2018 |
| Experimental Studies of the Effects of Progesterone on the Functional Activity of P-Glycoprotein | Pharmaceutical Chemistry Journal | 2018 |
| Renal Organic Cation and Anion Transport: From Physiology to Genes | | 2018 |
| In Vitro and In Vivo Investigation of Potential for Complex CYP3A Interaction for PF-00251802 (Dagrocorat), a Novel Dissociated Agonist of the Glucocorticoid Receptor | Clinical Pharmacology in Drug Development | 2018 |
| Development of Guanfacine Extended-Release Dosing Strategies in Children and Adolescents with ADHD Using a Physiologically Based Pharmacokinetic Model to Predict Drug-Drug Interactions with Moderate CYP3A4 Inhibitors or Inducers | Paediatric Drugs | 2018 |
| Prediction of Drug-Drug Interaction between Tacrolimus and Principal Ingredients of Wuzhi Capsule in Chinese Healthy Volunteers Using Physiologically-Based Pharmacokinetic Modelling | Basic and Clinical Pharmacology and Toxicology | 2018 |
| Effects of rifampin, itraconazole and esomeprazole on the pharmacokinetics of alisertib, an investigational aurora a kinase inhibitor in patients with advanced malignancies | Investigational New Drugs | 2018 |
| Clinical evaluation of P-glycoprotein inhibition by venetoclax: a drug interaction study with digoxin | Xenobiotica | 2018 |
| Drug interactions between non-rifamycin antibiotics and hormonal contraception: a systematic review | American Journal of Obstetrics and Gynecology | 2018 |
| In vitro drug-drug interactions of budesonide: inhibition and induction of transporters and cytochrome P450 enzymes | Xenobiotica | 2018 |
| Effects of Metformin and Furosemide on Rosuvastatin Pharmacokinetics in Healthy Volunteers: Implications for Their Use as Probe Drugs in a Transporter Cocktail | European Journal of Drug Metabolism and Pharmacokinetics | 2018 |
| In vitro evaluation of the inhibition and induction potential of olaparib, a potent poly(ADP-ribose) polymerase inhibitor, on cytochrome P450 | Xenobiotica | 2018 |
| Transport properties of valsartan, sacubitril and its active metabolite (LBQ657) as determinants of disposition | Xenobiotica | 2018 |
| Interpretation, Integration, and Implementation of In Vitro Assay Data: The Predictive Toxicity Challenge | Methods in Pharmacology and Toxicology | 2018 |
| Relationships of Changes in Pharmacokinetic Parameters of Substrate Drugs in Drug-Drug Interactions on Metabolizing Enzymes and Transporters | Journal of Clinical Pharmacology | 2018 |
| Effects of a Fixed-Dose Co-Formulation of Daclatasvir, Asunaprevir, and Beclabuvir on the Pharmacokinetics of a Cocktail of Cytochrome P450 and Drug Transporter Substrates in Healthy Subjects | Drugs in R and D | 2018 |
| Reverse Translation of US Food and Drug Administration Reviews of Oncology New Molecular Entities Approved in 2011-2017: Lessons Learned for Anticancer Drug Development | Clinical and Translational Science | 2018 |
| In vitro studies and in silico predictions of fluconazole and CYP2C9 genetic polymorphism impact on siponimod metabolism and pharmacokinetics | European Journal of Clinical Pharmacology | 2018 |
| Pharmacokinetic/pharmacodynamic drug-drug interactions of avatrombopag when coadministered with dual or selective CYP2C9 and CYP3A interacting drugs | British Journal of Clinical Pharmacology | 2018 |
| Pharmacokinetic Drug Interaction Study of Bazedoxifene and Ibuprofen | Clinical Pharmacology in Drug Development | 2018 |
| Development of a Physiologically Based Pharmacokinetic Model for Sinogliatin, a First-in-Class Glucokinase Activator, by Integrating Allometric Scaling, In Vitro to In Vivo Exploration and Steady-State Concentration-Mean Residence Time Methods: Mechanistic Understanding of its Pharmacokinetics | Clinical Pharmacokinetics | 2018 |
| Novel Application of the Two-Period Microtracer Approach to Determine Absolute Oral Bioavailability and Fraction Absorbed of Ertugliflozin | Clinical and Translational Science | 2018 |
| Bidirectional Pharmacokinetic Interaction Between Amodiaquine and Pioglitazone in Healthy Subjects | Journal of Clinical Pharmacology | 2018 |
| The drug interaction potential of daprodustat when coadministered with pioglitazone, rosuvastatin, or trimethoprim in healthy subjects | Pharmacology Research and Perspectives | 2018 |
| Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects | European Journal of Drug Metabolism and Pharmacokinetics | 2018 |
| Disease-Drug Interactions in Inflammatory States via Effects on CYP-Mediated Drug Clearance | Journal of Clinical Pharmacology | 2018 |
| The Role of Transporters in Drug Accumulation and Mitochondrial Toxicity | | 2018 |
| Development of an evidence evaluation and synthesis system for drug-drug interactions, and its application to a systematic review of HIV and malaria co-infection | PLoS ONE | 2017 |
| Importance of Publishing Adverse Drug Reaction Case Reports: Promoting Public Health and Advancing Pharmacology and Therapeutics | Drug Safety - Case Reports | 2017 |
| Validation of a total IC method which enables in vitro assessment of transporter inhibition under semi-physiological conditions | Xenobiotica | 2017 |
| Selexipag in Pulmonary Arterial Hypertension: Most Updated Evidence From Recent Preclinical and Clinical Studies | Journal of Clinical Pharmacology | 2017 |
| Unbound liver concentration is the true inhibitor concentration that determines cytochrome P450-mediated drug-drug interactions in rat liver | Xenobiotica | 2017 |
| Metabolic profile and pharmacokinetics of polyphyllin I, an anticancer candidate, in rats by UPLC-QTOF-MS/MS and LC-TQ-MS/MS | Biomedical Chromatography | 2017 |
| Pharmacokinetics of Venetoclax, a Novel BCL-2 Inhibitor, in Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Non-Hodgkin Lymphoma | Journal of Clinical Pharmacology | 2017 |
| Clinical Pharmacokinetics and Pharmacodynamics of Afatinib | Clinical Pharmacokinetics | 2017 |
| Use of a cocktail probe to assess potential drug interactions with cytochrome P450 after administration of belatacept, a costimulatory immunomodulator | British Journal of Clinical Pharmacology | 2017 |
| Caco-2 cells - expression, regulation and function of drug transporters compared with human jejunal tissue | Biopharmaceutics and Drug Disposition | 2017 |
| Perspective: 4β-hydroxycholesterol as an emerging endogenous biomarker of hepatic CYP3A | Drug Metabolism Reviews | 2017 |
| Pharmacokinetics, Safety, and Tolerability of Single and Multiple Doses of ABT-493: A First-In-Human Study | Journal of Pharmaceutical Sciences | 2017 |
| In vitro metabolism studies of natural products are crucial in the early development of medicines | Phytochemistry Reviews | 2017 |
| Clarithromycin, Midazolam, and Digoxin: Application of PBPK Modeling to Gain New Insights into Drug-Drug Interactions and Co-medication Regimens | AAPS Journal | 2017 |
| The potential of Epimedium koreanum Nakai for herb-drug interaction | Journal of Pharmacy and Pharmacology | 2017 |
| Systemic clearance and brain distribution of carbazole-based cyanine compounds as Alzheimer's disease drug candidates | Scientific Reports | 2017 |
| A Randomized Phase I Study to Assess the Effect of Alcohol on the Pharmacokinetics of an Extended-release Orally Disintegrating Tablet Formulation of Amphetamine in Healthy Adults | Clinical Therapeutics | 2017 |
| Drug-drug interactions between triazole antifungal agents used to treat invasive aspergillosis and immunosuppressants metabolized by cytochrome P450 3A4 | Transplant Infectious Disease | 2017 |
| Boceprevir and Antiretroviral Pharmacokinetic Interactions in HIV/HCV Co-infected Persons: AIDS Clinical Trials Group Study A5309s | Drugs in R and D | 2017 |
| Clinical Pharmacology Considerations for the Development of Immune Checkpoint Inhibitors | Journal of Clinical Pharmacology | 2017 |
| An easy and fast adenosine 5'-diphosphate quantification procedure based on hydrophilic interaction liquid chromatography-high resolution tandem mass spectrometry for determination of the in vitro adenosine 5'-triphosphatase activity of the human breast cancer resistance protein ABCG2 | Journal of Chromatography A | 2017 |
| Assessment of the Drug Interaction Potential of Unconjugated and GalNAc-Conjugated 2'-MOE-ASOs | Molecular Therapy - Nucleic Acids | 2017 |
| Mechanistic in vitro studies confirm that inhibition of the renal apical efflux transporter multidrug and toxin extrusion (MATE) 1, and not altered absorption, underlies the increased metformin exposure observed in clinical interactions with cimetidine, trimethoprim or pyrimethamine | Pharmacology Research and Perspectives | 2017 |
| Validation of a microdose probe drug cocktail for clinical drug interaction assessments for drug transporters and CYP3A | Clinical Pharmacology and Therapeutics | 2017 |
| Potent inhibition of human organic cation transporter 2 (hOCT2) by β-carboline alkaloids | Xenobiotica | 2017 |
| Inhibition of Intestinal OATP2B1 by the Calcium Receptor Antagonist Ronacaleret Results in a Significant Drug-Drug Interaction by Causing a 2-Fold Decrease in Exposure of Rosuvastatin | Drug Metabolism and Disposition | 2017 |
| Effects of Tenapanor on Cytochrome P450-Mediated Drug-Drug Interactions | Clinical Pharmacology in Drug Development | 2017 |
| Angiotensin II Receptor Blockers Inhibit the Generation of Epoxyeicosatrienoic Acid from Arachidonic Acid in Recombinant CYP2C9, CYP2J2 and Human Liver Microsomes | Basic and Clinical Pharmacology and Toxicology | 2017 |
| Investigating Transporter-Mediated Drug-Drug Interactions Using a Physiologically Based Pharmacokinetic Model of Rosuvastatin | CPT: Pharmacometrics and Systems Pharmacology | 2017 |
| Integrated safety analysis of rolapitant with coadministered drugs from phase II/III trials: an assessment of CYP2D6 or BCRP inhibition by rolapitant | Annals of Oncology | 2017 |
| Investigating the Additive Interaction of QT-Prolonging Drugs in Older People Using Claims Data | Drug Safety | 2017 |
| Metoprolol-pridopidine drug-drug interaction and food effect assessments of pridopidine, a new drug for treatment of Huntington's disease | British Journal of Clinical Pharmacology | 2017 |
| Absorption, Distribution, Metabolism, and Excretion of the Oral Prostaglandin D2 Receptor 2 Antagonist Fevipiprant (QAW039) in Healthy Volunteers and In Vitro | Drug Metabolism and Disposition | 2017 |
| Translational Research: Preclinical to Healthy Volunteer to Patient | AAPS Advances in the Pharmaceutical Sciences Series | 2017 |
| Risk Assessment Using Cytochrome P450 Time-Dependent Inhibition Assays at Single Time and Concentration in the Early Stage of Drug Discovery | Journal of Pharmaceutical Sciences | 2017 |
| About P-glycoprotein: a new drugable domain is emerging from structural data | Wiley Interdisciplinary Reviews: Computational Molecular Science | 2017 |
| Tenapanor administration and the activity of the H -coupled transporter PepT1 in healthy volunteers | British Journal of Clinical Pharmacology | 2017 |
| Physiologically Based Pharmacokinetic Modeling of Drug Transporters to Facilitate Individualized Dose Prediction | Journal of Pharmaceutical Sciences | 2017 |
| Progress in Prediction and Interpretation of Clinically Relevant Metabolic Drug-Drug Interactions: a Minireview Illustrating Recent Developments and Current Opportunities | Current Pharmacology Reports | 2017 |
| Drug Interaction Potential of Osilodrostat (LCI699) Based on Its Effect on the Pharmacokinetics of Probe Drugs of Cytochrome P450 Enzymes in Healthy Adults | Clinical Drug Investigation | 2017 |
| The influence of combination use of CYP450 inducers on the pharmacokinetics of voriconazole: a systematic review | Journal of Clinical Pharmacy and Therapeutics | 2017 |
| Effects of 6-paradol, an unsaturated ketone from gingers, on cytochrome P450-mediated drug metabolism | Bioorganic and Medicinal Chemistry Letters | 2017 |
| Evaluation of Drug-Drug Interaction Potential Between Sacubitril/Valsartan (LCZ696) and Statins Using a Physiologically Based Pharmacokinetic Model | Journal of Pharmaceutical Sciences | 2017 |
| FDA-approved drugs that interfere with laboratory tests: A systematic search of US drug labels | Critical Reviews in Clinical Laboratory Sciences | 2017 |
| Impact of curcumin on the pharmacokinetics of rosuvastatin in rats and dogs based on the conjugated metabolites | Xenobiotica | 2017 |
| Clinical Pharmacokinetics and Pharmacodynamics of Saxagliptin, a Dipeptidyl Peptidase-4 Inhibitor | Clinical Pharmacokinetics | 2017 |
| Pharmacokinetic Interactions Between Mirabegron and Metformin, Warfarin, Digoxin or Combined Oral Contraceptives | European Journal of Drug Metabolism and Pharmacokinetics | 2017 |
| The First-in-Class Potassium-Competitive Acid Blocker, Vonoprazan Fumarate: Pharmacokinetic and Pharmacodynamic Considerations | Clinical Pharmacokinetics | 2016 |
| Dosing Recommendations for Concomitant Medications During 3D Anti-HCV Therapy | Clinical Pharmacokinetics | 2016 |
| Effects of Cytochrome P450 Inhibition and Induction on the Phenotyping Metrics of the Basel Cocktail: A Randomized Crossover Study | Clinical Pharmacokinetics | 2016 |
| BDDCS Predictions, Self-Correcting Aspects of BDDCS Assignments, BDDCS Assignment Corrections, and Classification for more than 175 Additional Drugs | AAPS Journal | 2016 |
| Development of a Physiologically Based Pharmacokinetic Model for Itraconazole Pharmacokinetics and Drug-Drug Interaction Prediction | Clinical Pharmacokinetics | 2016 |
| Effect of Rifampin on the Pharmacokinetics of Apixaban, an Oral Direct Inhibitor of Factor Xa | American Journal of Cardiovascular Drugs | 2016 |
| Quantitative Prediction of Drug Interactions Caused by CYP1A2 Inhibitors and Inducers | Clinical Pharmacokinetics | 2016 |
| CYP3A activity: towards dose adaptation to the individual | Expert Opinion on Drug Metabolism and Toxicology | 2016 |
| The Nonmetabolized β-Blocker Nadolol Is a Substrate of OCT1, OCT2, MATE1, MATE2-K, and P-Glycoprotein, but Not of OATP1B1 and OATP1B3 | Molecular Pharmaceutics | 2016 |
| Clinical determinants of calcineurin inhibitor disposition: a mechanistic review | Drug Metabolism Reviews | 2016 |
| Generation and Characterization of a Breast Cancer Resistance Protein Humanized Mouse Model | Molecular Pharmacology | 2016 |
